866-997-4948(US-Canada Toll Free)

Head And Neck Cancer - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Aug 2012

Category :

Head and Neck Cancer

No. of Pages : 274 Pages

 

Head And Neck Cancer Pipeline Review, H2 2012

 

Global Markets Directs, \'Head And Neck Cancer Pipeline Review, H2 2012\', provides an overview of the Head And Neck Cancer therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. \'Head And Neck Cancer Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Head And Neck Cancer.
  • A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Head And Neck Cancer therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

 

Keywords

 

Head And Neck Cancer Therapeutic Products under Development, Key Players in Head And Neck Cancer Therapeutics, Head And Neck Cancer Pipeline Overview, Head And Neck Cancer Pipeline, Head And Neck Cancer Pipeline Assessment

Table of Contents


Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Head And Neck Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Head And Neck Cancer 12
Head And Neck Cancer Therapeutics under Development by Companies 14
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 31
Comparative Analysis 31
Mid Clinical Stage Products 32
Comparative Analysis 32
Early Clinical Stage Products 33
Comparative Analysis 33
Discovery and Pre-Clinical Stage Products 34
Comparative Analysis 34
Head And Neck Cancer Therapeutics Products under Development by Companies 35
Head And Neck Cancer Therapeutics Products under Investigation by Universities/Institutes 41
Companies Involved in Head And Neck Cancer Therapeutics Development 64
Johnson & Johnson 64
Boehringer Ingelheim GmbH 65
F. Hoffmann-La Roche Ltd. 66
Amgen Inc. 67
AstraZeneca PLC 68
Eli Lilly and Company 69
Viralytics Ltd. 70
GlaxoSmithKline plc 71
Genentech, Inc. 72
Inovio Biomedical Corporation 73
YM BioSciences Inc. 74
Symphogen A/S 75
Light Sciences Oncology, Inc. 76
Piramal Healthcare Limited 77
Celltrion, Inc. 78
Bio-Path Holdings, Inc. 79
Millennium Pharmaceuticals, Inc. 80
Novartis AG 81
ImClone Systems Incorporated 82
Daewoong Pharmaceutical Co., Ltd. 83
Eisai Co., Ltd. 84
Pfizer Inc. 85
Takara Holdings Inc. 86
Cell Therapeutics, Inc. 87
CEL-SCI Corporation 88
Celgene Corporation 89
Merck KGaA 90
Advaxis, Inc. 91
Neogenix Oncology Corporation 92
Idera Pharmaceuticals, Inc. 93
Bionomics Limited 94
NexMed, Inc. 95
Northwest Biotherapeutics, Inc. 96
Cleveland BioLabs, Inc. 97
Oncolytics Biotech Inc. 98
Oncothyreon Inc 99
Curis, Inc. 100
ADVENTRX Pharmaceuticals 101
Transgene SA 102
Nang Kuang Pharmaceutical Co., Ltd. 103
PCI Biotech Holding ASA 104
Avanti Therapeutics 105
Wilex AG 106
Acceleron Pharma, Inc. 107
Glycotope GmbH 108
Matrix Pharmaceutical Research 109
Hawthorn Pharmaceuticals, Inc. 110
PDS Biotechnology Corporation 111
Merrimack Pharmaceuticals, Inc. 112
Jennerex Biotherapeutics, Inc. 113
Oncolys BioPharma Inc. 114
Globeimmune, Inc. 115
Etubics Corporation 116
VentiRx Pharmaceuticals, Inc. 117
IRX Therapeutics, Inc. 118
Pique Therapeutics 119
Cellceutix Pharmaceuticals, Inc. 120
PNP Therapeutics, Inc. 121
Eurofarma 122
Theradex Systems, Inc. 123
TAU Therapeutics, LLC 124
Boneca Corporation 125
CytomX, LLC. 126
Head And Neck Cancer Therapeutics Assessment 127
Assessment by Monotherapy Products 127
Assessment by Combination Products 128
Assessment by Route of Administration 129
Assessment by Molecule Type 131
Drug Profiles 133
Multikine - Drug Profile 133
Vectibix - Drug Profile 135
Tykerb - Drug Profile 138
Tirazone - Drug Profile 139
Taxotere + Cisplatin + 5-Fluorouracil + Carboplatin + Radiation Therapy - Drug Profile 140
Carboplatin + Radiotherapy - Drug Profile 142
Gefitinib - Drug Profile 143
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 145
Cisplatin + Radiation Therapy - Drug Profile 147
Cisplatin + Docetaxel + Fluorouracil + Bevacizumab - Drug Profile 148
Erbitux + Carboplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 150
Docetaxel + Cisplatin + Hydroxyurea + 5-Fluorouracil - Drug Profile 152
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 154
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 156
Erbitux + Cisplatin + 5-Fluorouracil - Drug Profile 157
Cetuximab + Radiation Therapy - Drug Profile 159
Vectibix + Cisplatin + 5-FU - Drug Profile 160
Cisplatin + Docetaxel + Fluorouracil + Radiation therapy - Drug Profile 162
Reolysin + Paclitaxel + Carboplatin - Drug Profile 164
Afatinib - Drug Profile 167
Paclitaxel - Drug Profile 169
Bleomycin Sulfate + Fluorouracil + Leucovorin Calcium + Methotrexate + Vincristine Sulfate + Radiation Therapy - Drug Profile 170
Radiation Therapy + Cetuximab - Drug Profile 172
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 174
Tarceva + Cisplatin + Paclitaxel - Drug Profile 176
Biomab EGFR - Drug Profile 178
Docetaxel + Iressa - Drug Profile 180
Cisplatin + Paclitaxel + Radiotherapy - Drug Profile 182
Panitumumab + Cisplatin + Radiation Therapy - Drug Profile 184
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 186
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 188
Zalutumumab + Radiotherapy - Drug Profile 190
cisplatin + fluorouracil + radiation therapy - Drug Profile 191
Carboplatin + Radiation Therapy - Drug Profile 193
Tykerb + Cisplatin - Drug Profile 194
Nimotuzumab + Cisplatin - Drug Profile 196
Bevacizumab + Cisplatin + Docetaxel + Fluorouracil - Drug Profile 198
Panitumumab - Drug Profile 200
Cisplatin + Radiation Therapy - Drug Profile 201
Tegafur-Uracil - Drug Profile 202
Zalutumumab + Cisplatin - Drug Profile 203
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 205
Cetuximab + Cisplatin - Drug Profile 206
Cetuximab + Cisplatin - Drug Profile 208
Docetaxel + Cisplatin + Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 209
Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile 210
Docetaxel + Cisplatin + 5-Fluorouracil + Erbitux + Radiation Therapy - Drug Profile 211
Nimotuzumab - Drug Profile 213
S-1 - Drug Profile 214
Multikine + Cyclophosphamide + Indomethacin + Zinc - Drug Profile 215
Multikine + Cisplatin - Drug Profile 217
Nimorazole + Radiotherapy - Drug Profile 219
Head And Neck Cancer Therapeutics Drug Profile Updates 220
Head And Neck Cancer Therapeutics Discontinued Products 232
Head And Neck Cancer Therapeutics - Dormant Products 237
Head And Neck Cancer Product Development Milestones 261
Featured News & Press Releases 261


Appendix 269
Methodology 269
Coverage 269
Secondary Research 269
Primary Research 269
Expert Panel Validation 269
Contact Us 270
Disclaimer 270

List of Table


Number of Products Under Development for Head And Neck Cancer, H2 2012 16
Products under Development for Head And Neck Cancer Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Development by Companies, H2 2012 (Contd..4) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 25
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 34
Comparative Analysis by Late Stage Development, H2 2012 35
Comparative Analysis by Mid Clinical Stage Development, H2 2012 36
Comparative Analysis by Early Clinical Stage Development, H2 2012 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 38
Products under Development by Companies, H2 2012 39
Products under Development by Companies, H2 2012 (Contd..1) 40
Products under Development by Companies, H2 2012 (Contd..2) 41
Products under Development by Companies, H2 2012 (Contd..3) 42
Products under Development by Companies, H2 2012 (Contd..4) 43
Products under Development by Companies, H2 2012 (Contd..5) 44
Products under Investigation by Universities/Institutes, H2 2012 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 67
Johnson & Johnson, H2 2012 68
Boehringer Ingelheim GmbH, H2 2012 69
F. Hoffmann-La Roche Ltd., H2 2012 70
Amgen Inc., H2 2012 71
AstraZeneca PLC, H2 2012 72
Eli Lilly and Company, H2 2012 73
Viralytics Ltd., H2 2012 74
GlaxoSmithKline plc, H2 2012 75
Genentech, Inc., H2 2012 76
Inovio Biomedical Corporation, H2 2012 77
YM BioSciences Inc., H2 2012 78
Symphogen A/S, H2 2012 79
Light Sciences Oncology, Inc., H2 2012 80
Piramal Healthcare Limited, H2 2012 81
Celltrion, Inc., H2 2012 82
Bio-Path Holdings, Inc., H2 2012 83
Millennium Pharmaceuticals, Inc., H2 2012 84
Novartis AG, H2 2012 85
ImClone Systems Incorporated, H2 2012 86
Daewoong Pharmaceutical Co., Ltd., H2 2012 87
Eisai Co., Ltd., H2 2012 88
Pfizer Inc., H2 2012 89
Takara Holdings Inc., H2 2012 90
Cell Therapeutics, Inc., H2 2012 91
CEL-SCI Corporation, H2 2012 92
Celgene Corporation, H2 2012 93
Merck KGaA, H2 2012 94
Advaxis, Inc., H2 2012 95
Neogenix Oncology Corporation, H2 2012 96
Idera Pharmaceuticals, Inc., H2 2012 97
Bionomics Limited, H2 2012 98
NexMed, Inc., H2 2012 99
Northwest Biotherapeutics, Inc., H2 2012 100
Cleveland BioLabs, Inc., H2 2012 101
Oncolytics Biotech Inc., H2 2012 102
Oncothyreon Inc, H2 2012 103
Curis, Inc., H2 2012 104
ADVENTRX Pharmaceuticals, H2 2012 105
Transgene SA, H2 2012 106
Nang Kuang Pharmaceutical Co., Ltd., H2 2012 107
PCI Biotech Holding ASA, H2 2012 108
Avanti Therapeutics, H2 2012 109
Wilex AG, H2 2012 110
Acceleron Pharma, Inc., H2 2012 111
Glycotope GmbH, H2 2012 112
Matrix Pharmaceutical Research, H2 2012 113
Hawthorn Pharmaceuticals, Inc., H2 2012 114
PDS Biotechnology Corporation, H2 2012 115
Merrimack Pharmaceuticals, Inc., H2 2012 116
Jennerex Biotherapeutics, Inc., H2 2012 117
Oncolys BioPharma Inc., H2 2012 118
Globeimmune, Inc., H2 2012 119
Etubics Corporation, H2 2012 120
VentiRx Pharmaceuticals, Inc., H2 2012 121
IRX Therapeutics, Inc., H2 2012 122
Pique Therapeutics, H2 2012 123
Cellceutix Pharmaceuticals, Inc., H2 2012 124
PNP Therapeutics, Inc., H2 2012 125
Eurofarma, H2 2012 126
Theradex Systems, Inc., H2 2012 127
TAU Therapeutics, LLC, H2 2012 128
Boneca Corporation, H2 2012 129
CytomX, LLC., H2 2012 130
Assessment by Monotherapy Products, H2 2012 131
Assessment by Combination Products, H2 2012 132
Assessment by Stage and Route of Administration, H2 2012 134
Assessment by Stage and Molecule Type, H2 2012 136
Head And Neck Cancer Therapeutics Drug Profile Updates 224
Head And Neck Cancer Therapeutics Discontinued Products 236
Head And Neck Cancer Therapeutics Discontinued Products (Contd..1) 237
Head And Neck Cancer Therapeutics Discontinued Products (Contd..2) 238
Head And Neck Cancer Therapeutics Discontinued Products (Contd..3) 239
Head And Neck Cancer Therapeutics Discontinued Products (Contd..4) 240
Head And Neck Cancer Therapeutics Dormant Products 241
Head And Neck Cancer Therapeutics Dormant Products (Contd..1) 242
Head And Neck Cancer Therapeutics Dormant Products (Contd..2) 243
Head And Neck Cancer Therapeutics Dormant Products (Contd..3) 244
Head And Neck Cancer Therapeutics Dormant Products (Contd..4) 245
Head And Neck Cancer Therapeutics Dormant Products (Contd..5) 246
Head And Neck Cancer Therapeutics Dormant Products (Contd..6) 247
Head And Neck Cancer Therapeutics Dormant Products (Contd..7) 248
Head And Neck Cancer Therapeutics Dormant Products (Contd..8) 249
Head And Neck Cancer Therapeutics Dormant Products (Contd..9) 250
Head And Neck Cancer Therapeutics Dormant Products (Contd..10) 251
Head And Neck Cancer Therapeutics Dormant Products (Contd..11) 252
Head And Neck Cancer Therapeutics Dormant Products (Contd..12) 253
Head And Neck Cancer Therapeutics Dormant Products (Contd..13) 254
Head And Neck Cancer Therapeutics Dormant Products (Contd..14) 255
Head And Neck Cancer Therapeutics Dormant Products (Contd..15) 256
Head And Neck Cancer Therapeutics Dormant Products (Contd..16) 257
Head And Neck Cancer Therapeutics Dormant Products (Contd..17) 258
Head And Neck Cancer Therapeutics Dormant Products (Contd..18) 259
Head And Neck Cancer Therapeutics Dormant Products (Contd..19) 260
Head And Neck Cancer Therapeutics Dormant Products (Contd..20) 261
Head And Neck Cancer Therapeutics Dormant Products (Contd..21) 262
Head And Neck Cancer Therapeutics Dormant Products (Contd..22) 263
Head And Neck Cancer Therapeutics Dormant Products (Contd..23) 264

List of Chart


Number of Products under Development for Head And Neck Cancer, H2 2012 16
Products under Development for Head And Neck Cancer - Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 24
Late Stage Products, H2 2012 35
Mid Clinical Stage Products, H2 2012 36
Early Clinical Stage Products, H2 2012 37
Discovery and Pre-Clinical Stage Products, H2 2012 38
Assessment by Monotherapy Products, H2 2012 131
Assessment by Combination Products, H2 2012 132
Assessment by Route of Administration, H2 2012 133
Assessment by Stage and Route of Administration, H2 2012 134
Assessment by Molecule Type, H2 2012 135
Assessment by Stage and Molecule Type, H2 2012 136

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *